Renger G. Tiessen

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

Shenghui He, Patrick J. Roberts, Jessica A. Sorrentino et al. · Science Translational Medicine · 2017 · 144 citations

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Leona Ling, Jan Hillson, Renger G. Tiessen et al. · Clinical Pharmacology & Therapeutics · 2018 · 140 citations · Full text

Clinical Immunology, Immunohematology, Immunodeficiencies +24

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Teddy Kosoglou, Larisa Reyderman, Renger G. Tiessen et al. · European Journal of Clinical Pharmacology · 2011 · 93 citations

Healthy Subjects, Pharmacological Study, Sch 530348 +6

Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir

Marc Bifano, Carey Hwang, B. Oosterhuis et al. · Antiviral Therapy · 2013 · 92 citations

Pharmacodynamic interaction between ezetimibe and rosuvastatin

Teddy Kosoglou, Paul Statkevich, Bo Yang et al. · Current Medical Research and Opinion · 2004 · 69 citations